Phase 3 N=60 D Mannose in Recurrent Urinary Tract Infections
Recurrent Urinary Tract Infection
Primary: Days — 200; 52.7 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=614 Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
Postmenopausal Symptoms
Primary: Mean Change in Frequency of Moderate to Severe VMS From Baseline at Week 4 and Week 12. — 11.79; 11.65; -4.71; -3.36 Hot flash per day — p=<0.0001
Phase 3 N=143 Behavioral Treatment of Overactive Bladder in Men
Overactive Bladder
Primary: 24-hour Voiding Frequency — 9.1; 9.5 voids per 24-hour day — p=.001
Phase 3 N=504 Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 — 19.0; 30.4; 38.1 percentage of participants — p=0.0001
Phase 3 N=505 PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 — 18.3; 28.4; 40.7 percentage of participants — p=<0.0001
Phase 3 N=158 An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis
Psoriasis
Primary: Percentage of Participants With Greater Than or Equal to 75 Percent (%) Improvement in Psoriasis Area and Severity Index (PASI) Score — 6.5; 59.4; 67.7 Percentage of…
Phase 3 N=181 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
Symptomatic Neurogenic Orthostatic Hypotension (NOH) · Non-diabetic Neuropathy · Primary Autonomic Failure
Primary: Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1) — 1.3; 1.9 units on a scale — p=0.509
Phase 3 N=51 A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease
Orthostatic Hypotension · Parkinson's Disease
Primary: 306A Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ) — -2.2; -2.1 units on a scale — p=0.978
Phase 3 N=6,528 Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness
Venous Thrombosis · Pulmonary Embolism
Primary: Incidence of Composite of Adjudicated Total Venous Thromboembolism (VTE) and VTE-related Death During the Intended Treatment Period - Primary Efficacy Population — 2.71…
Phase 3 N=812 A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.
Diabetes Mellitus, Type 2
Primary: Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 32 — -0.78; -0.99 Percentage of HbA1c in the blood — p=0.0846
Phase 3 N=644 A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older Adults
Rabies
Primary: Non-inferiority in Immune Response of the Zagreb Postexposure Schedule of Rabipur to That of the Conventional Essen Postexposure Schedule of Rabipur as Measured by GMC…
Phase 3 N=16 Prevention of Low Blood Pressure in Persons With Tetraplegia
Hypotension · Spinal Cord Injury
Primary: Systolic Blood Pressure During Head-up Tilt — 91.80; 108.10; 112.04; 129.94 mmHg
Phase 3 N=1,090 Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
Sexual Dysfunctions, Psychological
Primary: The Change From Baseline to Week 24 in the Score of the Female Sexual Function Index Desire Domain. — 1.0; 0.7 units on a scale
Phase 3 N=488 PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 — 18.9; 37.4; 32.1 percentage of participants — p=0.0060
Phase 3 N=87 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Acute Lymphoblastic Leukemia in Remission · Acute Myeloid Leukemia in Remission · Aggressive Non-Hodgkin Lymphoma
Primary: Overall Survival — 65; 54 percentage of participants — p=.09